Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 35.22.
Forward PE Ratio (35.22) = Close Price ($515.15) / Consensus Forward EPS ($14.77)
FORWARD PE RATIO
35.22
SECTOR MEDIAN · HEALTHCARE
19.76
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
+78.28%
vs the sector median at left
IDEXX Laboratories, Inc.
Market Cap
$40.64B
Forward PE Ratio
35.22
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $40.64B | 35.22 |
| Agilent Technologies, Inc. (A)vs › | $40.89B | 23.68 |
| IQVIA Holdings Inc. (IQV)vs › | $42.30B | 19.99 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.92B | 18.55 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.52B | 38.72 |
| Alcon Inc. (ALC)vs › | $33.37B | 19.80 |
| Humana Inc. (HUM)vs › | $48.03B | 44.03 |
| ResMed Inc. (RMD)vs › | $31.91B | 19.87 |
| Becton, Dickinson and Company (BDX)vs › | $49.54B | 14.14 |
| Centene Corp. (CNC)vs › | $31.66B | 13.45 |
Trailing P/E
36.8
reported TTM EPS
Forward P/E
35.2
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $14.77 implies +4.6% EPS growth vs the reported trailing $14.12.
At today's $515.15 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $14.77 | $14.71 – $14.82 | 10 | 34.9x |
| 2027-12-31 | $16.77 | $16.35 – $17.10 | 10 | 30.7x |
| 2028-12-31 | $19.00 | $18.37 – $19.79 | 9 | 27.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute